Who Diabetes Compact?

Who Diabetes Compact
– The WHO Global Diabetes Compact was launched at a Global Diabetes Summit, co-hosted by the World Health Organization and the Government of Canada, with the support of the University of Toronto, on 14 April 2021. : The WHO Global Diabetes Compact

What is the world health Organization doing about diabetes?

WHO response – WHO aims to stimulate and support the adoption of effective measures for the surveillance, prevention and control of diabetes and its complications, particularly in low- and middle-income countries. To this end, WHO:

provides scientific guidelines for the prevention of major noncommunicable diseases including diabetes;develops norms and standards for diabetes diagnosis and care;builds awareness on the global epidemic of diabetes, marking World Diabetes Day (14 November); andconducts surveillance of diabetes and its risk factors.

The WHO Global report on diabetes provides an overview of the diabetes burden, interventions available to prevent and manage diabetes, and recommendations for governments, individuals, the civil society and the private sector. The WHO module on diagnosis and management of type 2 diabetes brings together guidance on diagnosis, classification and management of type 2 diabetes in one document.

  1. In April 2021 WHO launched the Global Diabetes Compact, a global initiative aiming for sustained improvements in diabetes prevention and care, with a particular focus on supporting low- and middle-income countries.
  2. The Compact is bringing together all stakeholders to work on a shared vision of reducing the risk of diabetes and ensuring that all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable and quality treatment and care.

In May 2021, the World Health Assembly agreed a Resolution on strengthening prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes.

  1. In May 2022 the World Health Assembly endorsed five global diabetes coverage and treatment targets to be achieved by 2030.
  2. References 1.
  3. Global Burden of Disease Collaborative Network.
  4. Global Burden of Disease Study 2019. Results.
  5. Institute for Health Metrics and Evaluation.2020 ( https://vizhub.healthdata.org/gbd-results/ ).2.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio et al.

Lancet.2010; 26;375:2215-2222.3, Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study GBD 2019 Blindness and Vision Impairment Collaborators* on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study† Lancet Global Health 2021;9:e141-e160.4.2014 USRDS annual data report: Epidemiology of kidney disease in the United States,

United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014:188–210.

How do type 1 diabetics cope?

– A good support system is essential to coping with type 1 diabetes. Spending time with friends and family or talking with someone you trust are great ways to manage diabetes distress. You can also join a diabetes support group to meet other people who are living with type 1 diabetes.

Support groups are especially helpful if you feel alone or different because of your diabetes. Many hospitals offer diabetes support groups, or you can ask a member of your diabetes care team for a referral. Getting support from others can also reduce your chance of developing a mental health disorder.

If you have type 1 diabetes, you’re at increased risk of developing mental health disorders, including depression and anxiety. People with mental health disorders may find it harder to manage their diabetes and stick to their prescribed medication regimen.

What is the new diabetes discovery?

Who Diabetes Compact Share on Pinterest From new medications to immune therapy, a number of innovations in the management and treatment of diabetes were announced in 2022. Andriy Onufriyenko/Getty Images

Several innovations in the management and treatment of diabetes were announced this year. Among them was the approval of a new medication, tirzepatide, which improves control of the measure of blood sugar levels in adults with type 2 diabetes. Health experts say the approval of the first immune therapy, which can delay the onset of type 1 diabetes, is also a major medical breakthrough.

For the 37.3 million Americans who are living with diabetes, 2022 marked a year of innovations. This included treatments for better managing blood sugar control for type 2 diabetes while the Food and Drug Administration approved the first drug to delay the onset of type 1 diabetes.

  • Diabetes is a metabolic disease that leads to high blood glucose or blood sugar.
  • There are three main forms of the disease, type 1, type 2, and gestational diabetes, according to the Centers for Disease Control and Prevention (CDC),
  • Another form, type 1.5 diabetes, is relatively rare, an autoimmune disorder that appears gradually during one’s adult years and actually is unable to be treated through changes to lifestyle behaviors or diet.
See also:  How Do You Test For Type 1 Diabetes?

If you have a form of diabetes, your body may not generate enough insulin (the hormone that transports energy-generating sugar from the bloodstream to your cells) or might not successfully make use of the insulin it does produce. High blood glucose levels that remain unchecked can result in something of a negative domino effect on your health.

  • This could mean damage to crucial organs and systems such as your blood vessels, kidneys, and eyes, among others.
  • When reflecting on the diabetes research and drug developments of the past year, Dr.
  • Matthew Freeby, the director of the UCLA Gonda Diabetes Center, told Healthline that “each of these breakthroughs are exciting because they make diabetes a little easier to treat and take care of on a day-to-day basis.” Freeby explained that anyone living with type 1 or type 2 diabetes knows these are chronic conditions that can be difficult to manage in the day-to-day.

“Anything we can do to make things a little bit easier is really important, and I think each of these breakthroughs to help patientsand potentially improve outcomes in the longer term,” Freeby said. Here’s a look at some of the most promising innovations, medical breakthroughs, and headlines in diabetes management and prevention from 2022.

Did the Queen have diabetes?

Her Majesty the Queen welcomes 100 year anniversary of insulin treatment Her Majesty The Queen, our Patron, has written to us to extend her good wishes to all those living with diabetes and their families and to mark the 100 year anniversary of the first time insulin was successfully used to treat a human.

  1. On the 100th anniversary of the first successful treatment with insulin, I send my warmest good wishes to all those living with and affected by diabetes.
  2. This milestone provides an opportunity to celebrate this breakthrough that continues to improve the lives of people living with diabetes around the world.

I extend my thanks for the ongoing hard work and dedication of the scientific, medical and research communities, who work tirelessly to further advance their understanding of the condition.

“As Patron of Diabetes UK, I send my greetings to all staff and volunteers, and hope that the discoveries yet to come bring you ever closer to achieving your vision of a world where diabetes can do no harm.”Elizabeth R.11 January, 2022Find out more about the,

: Her Majesty the Queen welcomes 100 year anniversary of insulin treatment

Do diabetics get depressed?

Stress and Anxiety – Stress is part of life, from traffic jams to family demands to everyday diabetes care. You can feel stress as an emotion, such as fear or anger, as a physical reaction like sweating or a racing heart, or both. If you’re stressed, you may not take as good care of yourself as usual.

  • Your blood sugar levels can be affected too—stress hormones make blood sugar rise or fall unpredictably, and stress from being sick or injured can make your blood sugar go up.
  • Being stressed for a long time can lead to other health problems or make them worse.
  • Anxiety—feelings of worry, fear, or being on edge—is how your mind and body react to stress.

People with diabetes are 20% more likely than those without diabetes to have anxiety at some point in their life. Managing a long-term condition like diabetes is a major source of anxiety for some. Studies show that therapy for anxiety usually works better than medicine, but sometimes both together works best.

Getting active : even a quick walk can be calming, and the effect can last for hours. Doing some relaxation exercises, like meditation or yoga. Calling or texting a friend who understands you (not someone who is causing you stress!). Grabbing some “you” time. Take a break from whatever you’re doing. Go outside, read something fun—whatever helps you recharge. Limiting alcohol and caffeine, eating healthy food, and getting enough sleep.

Anxiety can feel like low blood sugar and vice versa. It may be hard for you to recognize which it is and treat it effectively. If you’re feeling anxious, try checking your blood sugar and treat it if it’s low. There will always be some stress in life. But if you feel overwhelmed, talking to a mental health counselor can help. Ask your doctor for a referral. Getting help for a mental health issue can help you manage diabetes, too.

What is type 7 diabetes?

UniProtKB/Swiss-Prot: 73 A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

Can pancreas produce insulin again?

Researchers have discovered that patients with type 1 diabetes can regain the ability to produce insulin. They showed that insulin-producing cells can recover outside the body. Type 1 diabetes is a serious disease that affects many children and adolescents.

  • The disease causes the pancreas to stop producing insulin, a hormone that regulates blood sugar levels.
  • When blood sugar levels are too high, the smallest blood vessels in the body eventually become damaged.
  • This can lead to serious health problems further down the line, including heart attacks, stroke, blindness, kidney failure and foot amputations.
See also:  How To Stop Diabetes Hunger?

Professor Knut Dahl-Jørgensen and doctoral student Lars Krogvold are leading a research project, (DiViD), in which they want to ascertain among other things whether a virus in the pancreas might cause type 1 diabetes. They have previously discovered viruses in hormone-producing cells, the so-called islets of Langerhans, in the pancreas. Lars Krogvold, doctoral student at the University of Oslo and paediatrician at Oslo University Hospital. Photo: Private

What is the new breakthrough for type 2 diabetes?

Known as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, these drugs help the kidneys remove sugar from a person’s blood. Not only does this improve blood-sugar control in people with Type 2 diabetes, but it also helps protect them from heart failure and kidney disease—two common and serious complications.

What is the latest technology for diabetes?

News Release Wednesday, September 28, 2022 Next-generation technology maintains blood glucose levels by automatically delivering insulin. Who Diabetes Compact iLet bionic pancreas device Beta Bionics A device known as a bionic pancreas, which uses next-generation technology to automatically deliver insulin, was more effective at maintaining blood glucose (sugar) levels within normal range than standard-of-care management among people with type 1 diabetes, a new multicenter clinical trial has found.

The trial was primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, and published in the New England Journal of Medicine, Automated insulin delivery systems, also called artificial pancreas or closed-loop control systems, track a person’s blood glucose levels using a continuous glucose monitor and automatically deliver the hormone insulin when needed using an insulin pump.

These systems replace reliance on testing glucose level by fingerstick, continuous glucose monitor with separate insulin delivery through multiple daily injections, or a pump without automation. Compared to other available artificial pancreas technologies, the bionic pancreas requires less user input and provides more automation because the device’s algorithms continually adjust insulin doses automatically based on users’ needs.

Users initialize the bionic pancreas by entering their body weight into the device’s dosing software at the time of first use. Users of the bionic pancreas also do not have to count carbohydrates, nor initiate doses of insulin to correct for high blood glucose. In addition, health care providers do not need to make periodic adjustments to the settings of the device.

“Keeping tight control over blood glucose is important in managing diabetes and is the best way to prevent complications like eye, nerve, kidney, and cardiovascular disease down the road,” said Dr. Guillermo Arreaza-Rubín, director of NIDDK’s diabetes technology program.

“The bionic pancreas technology introduces a new level of ease to the day-to-day management of type 1 diabetes, which may contribute to improved quality of life.” The 13-week trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6 to 79 years who had type 1 diabetes and had been using insulin for at least one year.

Participants were randomly assigned to either a treatment group using the bionic pancreas device or a standard-of-care control group using their personal pre-study insulin delivery method. All participants in the control group were provided with a continuous glucose monitor, and nearly one-third of the control group were using commercially available artificial pancreas technology during the study.

In participants using the bionic pancreas, glycated hemoglobin, a measure of a person’s long-term blood glucose control, improved from 7.9% to 7.3%, yet remained unchanged among the standard-of-care control group. The bionic pancreas group participants spent 11% more time, approximately 2.5 hours per day, within the targeted blood glucose range compared to the control group.

These results were similar in youth and adult participants, and improvements in blood glucose control were greatest among participants who had higher blood glucose levels at the beginning of the study. “Our observation that this system can safely improve glucose control to the degree we found, and do so despite requiring much less input from users and their health care providers, has important implications for children and adults living with diabetes,” said Dr.

Steven Russell, study chair, associate professor of medicine at Harvard Medical School, and staff physician at the Massachusetts General Hospital in Boston. Hyperglycemia, or high blood glucose, caused by problems with insulin pump equipment, was the most frequently reported adverse event in the bionic pancreas group.

The number of mild hypoglycemia events, or low blood glucose, was low and was not different between the groups. The frequency of severe hypoglycemia was not statistically different between the standard of care and bionic pancreas groups. Four companion papers were also published in Diabetes Technology and Therapeutics, two of which provided more detailed results among the adult and youth participants.

  • The third paper reported results from an extension study in which the participants from the standard-of-care control group switched to using the bionic pancreas for 13 weeks and experienced improvements in glucose control similar to the bionic pancreas group in the randomized trial.
  • In the fourth paper, results showed that using the bionic pancreas with a faster-acting insulin in 114 adult participants improved glucose control as effectively as using the device with standard insulin.
See also:  How To Test For Diabetes?

“NIDDK’s decades-long investment in developing advanced technologies for diabetes management has reached another promising milestone and continues to provide significant return,” said NIDDK Director Dr. Griffin P. Rodgers. “While we continue to search for a cure for type 1 diabetes, devices like the bionic pancreas can allow people to worry less about their blood-glucose levels and focus more on living their fullest, healthiest lives.” Dr.

Edward Damiano, project principal investigator, professor of biomedical engineering at Boston University, and founder and executive chair of Beta Bionics, Inc., concurs. “The completion of this study represents a major milestone for the bionic pancreas initiative, which simply would not have been possible had it not been for the support provided by the NIDDK over the years.” The study is one of several pivotal trials funded by NIDDK to advance artificial pancreas technology and look at factors including safety, efficacy, user-friendliness, physical and emotional health of participants, and cost.

To date, these trials have provided the important safety and efficacy data needed for regulatory review and licensure to make the technology commercially available. The Jaeb Center for Health Research in Tampa, Florida, served as coordinating center. Funding for the study was provided by NIDDK grant 1UC4DK108612 to Boston University, by an Investigator-Initiated Study award from Novo Nordisk, and by Beta Bionics, Inc., which also provided the experimental bionic pancreas devices used in the study.

Insulin and some supplies were donated by Novo Nordisk, Eli Lilly, Dexcom, and Ascensia Diabetes Care. Partial support for the development of the experimental bionic pancreas device was provided by NIDDK Small Business Innovation Research (SBIR) grant 1R44DK120234 to Beta Bionics, Inc. The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases.

Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see https://www.niddk.nih.gov/,

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.

For more information about NIH and its programs, visit www.nih.gov, NIHTurning Discovery Into Health ® ###

What is the newest treatment for diabetes?

How does this new diabetes medication work? – Teplizumab is a monoclonal antibody that modifies T cells in a way that prolongs the pancreas’ ability to create insulin. The drug is specific to a molecule called CD3, which is the “cognate” component of the T cell, Dr. Herold explains. This modulates the immune cells and prevents them from attacking the cells in the pancreas that produce insulin.

What organizations are working to cure diabetes?

American Diabetes Association An organization whose mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

Is diabetes a global health concern?

A Dangerous Breakdown – Nearly half a billion people worldwide live with diabetes, and nearly 80% of those live in low- and middle-income countries. Nine in ten people with diabetes have Type 2 diabetes, which is increasing fastest in low- and middle-income countries.

  • People with type 2 diabetes cannot effectively use the insulin their body produces to regulate blood sugar.
  • Over time, high blood sugar damages many body systems, especially nerves and blood vessels.
  • Diabetes can lead to heart disease, stroke, kidney failure, blindness, and lower-limb amputation.
  • Recent research has also shown a connection between diabetes and dementia, hearing loss, and some forms of cancer.

Diabetes increases the risk of early death, and diabetes-related complications can lower quality of life. The high global burden of diabetes has a negative economic impact on individuals, health care systems, and nations.